In GBM, endothelial EGFL7–integrin signaling promotes the formation of new blood vessels and therapeutic EGFL7 blockade synergizes with anti-VEGF to more effectively impair tumor angiogenesis and growth72. Here, EGFL7 is linked to glioblastoma.